Compare HOLO & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOLO | MDXH |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | China | Belgium |
| Employees | 74 | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3M | 41.1M |
| IPO Year | N/A | 2021 |
| Metric | HOLO | MDXH |
|---|---|---|
| Price | $1.50 | $0.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 571.3K | ★ 758.2K |
| Earning Date | 08-10-2023 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.43 | $0.45 |
| 52 Week High | $7.39 | $5.33 |
| Indicator | HOLO | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 35.81 | 18.95 |
| Support Level | N/A | N/A |
| Resistance Level | $1.88 | $3.79 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 18.95 | 11.12 |
MicroCloud Hologram Inc provides holographic technology services. Its services include holographic light detection and ranging (LiDAR) solutions, holographic LiDAR point cloud algorithms architecture design, technical holographic imaging solutions, holographic LiDAR sensor chip design, and holographic vehicle intelligent vision technology to service customers that provide holographic driver assistance systems (ADAS). The company also provides holographic digital twin technology services for customers and has built a proprietary holographic digital twin technology resource library. MicroCloud's operating segments are: Holographic technology service, which generates maximum revenue, and Holographic solutions. Its revenues are mainly generated in the People's Republic of China (PRC).
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.